摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate

中文名称
——
中文别名
——
英文名称
methyl (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate
英文别名
methyl (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate;Methyl (1S)-3,4-Dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate;methyl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
methyl (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate化学式
CAS
——
化学式
C17H17NO2
mdl
——
分子量
267.327
InChiKey
DSYZPHZZKBSSHQ-INIZCTEOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PROCESS FOR PREPARING CHEMICALLY AND CHIRALLY PURE SOLIFENACIN BASE AND ITS SALTS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UNE SOLIFÉNACINE BASE DE PURETÉ CHIMIQUE ET DE PURETÉ CHIRALE ET DE SES SELS
    申请人:CADILA HEALTHCARE LTD
    公开号:WO2009087664A1
    公开(公告)日:2009-07-16
    The present invention provides improved processes for preparing chemically and chirally pure Solifenacin base. The present invention also provides for a composition comprising of a salt of Solifenacin having at least 98 % purity. The present invention also disclose certain new salts of Solifenacin as well as well as new polymorphic forms of Solifenacin hydrochloride and Solifenacin oxalate, in pure form.
    本发明提供了改进的制备化学纯和对映纯索利那辛碱的方法。本发明还提供了一种含有至少98%纯度的索利那辛盐的组合物。本发明还披露了索利那辛的某些新盐以及索利那辛盐酸盐和索利那辛草酸盐的新多形态,均为纯形式。
  • PROCESS FOR PREPARING (1S)-1-PHENYL-3,4-DIHYDRO-2(1H)-ISOQUINOLINE-CARBOXYLATE
    申请人:Shanghai Jingxin Biomedical Co., Ltd.
    公开号:US20150225348A1
    公开(公告)日:2015-08-13
    A process for preparation of (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate (Formula I), comprising reacting (1S)-1-phenyl-3,4-dihydro-2(1H)isoquinoline (Formula II) with carbon dioxide and an alkylating agent R-LG in the presence of a base to obtain the compound of Formula I in an organic solvent. In Formula I and II, R is an alkyl or a substituted alkyl; LG is a leaving group.
    一种制备(1S)-1-苯基-3,4-二氢-2(1H)-异喹啉羧酸酯(化学式I)的方法,包括在有机溶剂中,在碱的存在下,通过将(1S)-1-苯基-3,4-二氢-2(1H)-异喹啉(化学式II)与二氧化碳和烷基化试剂R-LG反应,从而得到化学式I的化合物。在化学式I和II中,R是烷基或取代烷基;LG是脱离基。
  • Method for producing solifenacin or salts thereof
    申请人:Inakoshi Masatoshi
    公开号:US20070185329A1
    公开(公告)日:2007-08-09
    There is provided a novel method for producing solifenacin or a salt thereof which is useful as a medicine, particularly a therapeutic agent and/or a preventive agent for a urinary organ system disease such as pollakiuria or urinary incontinence. Illustratively, there are provided (1) a method for producing solifenacin in which 2-(1H-imidazolylcarbonyl)-1-phenyltetrahydroisoquinoline is used as the starting material, (2) a method for producing solifenacin succinate in which (1RS)-phenyltetrahydroisoquinoline-carboxylic acid quinuclidinyl ester is used as the starting material, (3) a method for producing solifenacin in which a lower alkyl quinuclidinyl carbonate is used as the starting material and (4) a method for producing solifenacin in which phenyltetrahydroisoquinoline-carboxylic acid secondary lower alkyl or tertiary lower alkyl ester is used as the starting material and allowed to react with an alkali metal lower alkoxide.
    提供了一种新的制备索利费南或其盐的方法,该方法可用作药物,特别是用于治疗和/或预防尿生殖器官疾病,如尿频或尿失禁的治疗剂和/或预防剂。例如,提供了以下四种方法:(1)使用2-(1H-咪唑基)-1-苯基四氢异喹啉作为起始材料制备索利费南的方法;(2)使用(1RS)-苯基四氢异喹啉-羧酸奎尼克啶酯作为起始材料制备索利费南琥珀酸盐的方法;(3)使用较低烷基奎尼库啶碳酸酯作为起始材料制备索利费南的方法;(4)使用苯基四氢异喹啉-羧酸次级较低烷基或三级较低烷基酯作为起始材料,并与碱金属较低烷氧化物反应制备索利费南的方法。
  • PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT
    申请人:Astellas Pharma Inc.
    公开号:EP1757604A1
    公开(公告)日:2007-02-28
    There is provided a novel method for producing solifenacin or a salt thereof which is useful as a medicine, particularly a therapeutic agent and/or a preventive agent for a urinary organ system disease such as pollakiuria or urinary incontinence. Illustratively, there are provided (1) a method for producing solifenacin in which 2-(1H-imidazolylcarbonyl)-1-phenyltetrahydroisoquinoline is used as the starting material, (2) a method for producing solifenacin succinate in which (1RS)-phenyltetrahydroisoquinoline-carboxylic acid quinuclidinyl ester is used as the starting material, (3) a method for producing solifenacin in which a lower alkyl quinuclidinyl carbonate is used as the starting material and (4) a method for producing solifenacin in which phenyltetrahydroisoquinoline-carboxylic acid secondary lower alkyl or tertiary lower alkyl ester is used as the starting material and allowed to react with an alkali metal lower alkoxide.
    本发明提供了一种生产索利芬那新或其盐的新方法,该方法可用作药物,特别是泌尿器官系统疾病(如花粉尿症或尿失禁)的治疗剂和/或预防剂。示例性地,提供了(1)一种生产索利那新的方法,其中使用 2-(1H-咪唑羰基)-1-苯基四氢异喹啉作为起始原料;(2)一种生产索利那新琥珀酸酯的方法,其中使用(1RS)-苯基四氢异喹啉-羧酸奎宁酯作为起始原料、(4) 以苯基四氢异喹啉-羧酸仲低级烷基酯或叔低级烷基酯为起始原料,使其与碱金属低级烷氧基化合物反应,生产索利那新的方法。
  • [EN] A PROCESS FOR THE PREPARATION OF SOLIFENACIN SALTS AND THEIR INCLUSION INTO PHARMACEUTICAL DOSAGE FORMS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE SELS DE SOLIFÉNACINE ET INCLUSION DE CES DERNIERS DANS DES FORMES PHARMACEUTIQUES
    申请人:KRKA D D NOVO MESTO
    公开号:WO2010012459A3
    公开(公告)日:2010-08-05
查看更多